Clinical Trial Update: A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial to compare glofitamab as a single agent against investigator's choice in relapsed/refractory mantle cell lymphoma is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Columvi (glofitamab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Lymphoma | Phase 3 | Status: RECRUITING